New cancer drugs approvals underpinned by flawed evidence
A new report has shown that trial evidence alone is not enough when approving new cancer drugs and that an assessment of that evidence is also needed.
List view / Grid view
A new report has shown that trial evidence alone is not enough when approving new cancer drugs and that an assessment of that evidence is also needed.
By 2040, there will be over 1.2 million people living with dementia in England and Wales (an increase of 57% from 2016), due to increased life expectancy...
A plan to tackle “serious flaws in the creation, dissemination and implementation of medical evidence” is set out by experts from The BMJ and Oxford University’s Centre for Evidence Based Medicine.